Wesley Kaupinen
-
Wayne-Based Palvella Shares Soar as Lead Drug Candidate Meets Trial Goals
Wayne-based Palvella Therapeutics stock jumped 35 percent following the announcement of positive late-stage testing for Qtorin rapamycin, its lead drug candidate for a rare skin disease, writes John George for the Philadelphia…
Pioneer Partner
Founding Partners
Advertisement
Affiliate Partners
Community Partners
